Brought to you by 
Cerulean could get up to $1.2bn in NDC collaboration with Novartis; deal later canceled
23 Mar 2017
Executive Summary
Cerulean Pharma Inc. and Novartis Institutes for BioMedical Research Inc. will collaborate on the development of up to five nanoparticle-drug conjugate (NDC) candidates for cancer to which Novartis will have exclusive worldwide development, manufacturing, and commercialization rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cerulean could get up to $1.2bn in NDC collaboration with Novartis; deal later canceled
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice